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Introduction
Pregnancy is a dynamic state involving profound changes in the hormonal milieu of the mother which then signal adaptations in maternal nutrient metabolism. These adaptations are necessary in order to ensure a continuous supply of essential metabolites to support the growth and the development of the fetus as well as to provide the mother with sufficient energy stores to meet the demands of pregnancy and prepare for lactation (15, 26) . Pregnancy-induced changes in energy and nutrient metabolism follow a biphasic pattern. Early pregnancy is mainly anabolic since it is associated with augmented lipid deposition in maternal tissues as a consequence of maternal hyperphagia, increased de novo lipogenesis and enhanced insulin sensitivity (15) . In contrast, advanced pregnancy is an overall catabolic state involving augmented hydrolysis of stored lipids, hyperlipidemia and insulin resistance (15) .
Liver X receptors LXRα (NR1H3) and LXRβ (NR1H2) are oxysterol-activated nuclear receptors with key roles in the regulation of lipid metabolism. The two LXR isoforms share considerable sequence homology, but their tissue distribution differs: LXRα is highly expressed in liver, intestine, adipose tissue and macrophages whereas LXRβ is ubiquitously expressed (31) . LXR stimulates de novo lipogenesis by increasing the expression of sterol-regulatory element-binding protein-1c (SREBP1c), a master transcriptional regulator of fatty acid and triglyceride synthesis (32, 34) . LXR also binds directly to the promoters of the lipogenic enzymes fatty acid synthase (FAS), stearoyl-CoA desaturase 1 (SCD1) and acetyl-CoA carboxylase 1 (ACC1) (9, 18, 38) . Moreover, LXR plays a pivotal role in the regulation of cholesterol homeostasis: upon activation, it drives the efflux of cholesterol from non-hepatic tissues (e.g. macrophages and enterocytes), stimulates biliary excretion of the sterol in the liver and reduces the intestinal absorption of luminal sterols (27, 30, 32, 40) . However, there is limited understanding of how this nuclear receptor controls lipid metabolism in the physiological settings of pregnancy. Detailed knowledge of the molecular mechanisms responsible for lipid homeostasis during pregnancy is important as evidenced by the numerous reports demonstrating that failure to maintain the levels of circulating LXR Modulates Pregnancy Adaptations in Lipid Metabolism 5 lipids and lipoproteins within physiological ranges throughout gestation results in maternal dyslipidemia and fetal metabolic complications such as macrosomia and increased risk of type 2 diabetes mellitus in adulthood (19, 23, 39) .
We hypothesized that alterations in LXR activity could contribute to the gestational adaptations in lipid metabolism during pregnancy. Wild-type mice challenged with T0901317 (a potent and highly specific synthetic LXR agonist) throughout gestation and LXRα, β -/ -mutants were used to examine the role of LXR in pregnancy metabolic adaptations. In the present study, we identify changes in LXR signaling as an important factor that influences early-pregnancy lipogenesis in mice. Our data also suggest that LXR protects against abnormalities in fetoplacental lipid homeostasis during murine pregnancy.
Materials and Methods
Animal experiments. C57BL/6 mice were purchased from Harlan Laboratories (UK). LXR wild-type (WT) and LXRα, β -/ -(LXR DKO; model previously described (27) were maintained on a mixed strain background (C57BL/6: Sv129). All the mice were housed in a temperature and light-controlled environment with 12-hour light/ 12-hour dark cycles. Age-matched mice had free access to water and were fed a standard chow diet or chow supplemented with 0.012% T0901317 (Cayman Chemicals, UK) (34) (T0901317 diet). Pregnant females were sacrificed on days 7, 10, 14 and 18 of gestation. Tissues and sera were collected from chow-fed virgin controls and non-pregnant mice fed with a T0901317 diet for a period of 7, 10, 14 or 18 days. Mice, fasted for 4 hours with free access to water, were sacrificed by CO2
asphyxiation. All studies were conducted in conformity with the Public Health Service (PHS) Policy on
Humane Care and Use of Laboratory Animals and were approved by local animal ethics committees in King's College London and were authorised by the Home Office.
Lipid analysis. Lipid extraction was performed as previously described (25). Briefly, frozen tissue fragments were homogenized in Hank's Balanced Salt Solution using TissueLyser II system (Qiagen, UK) for 2 minutes at 30Hz and then centrifuged the samples at 12000 rpm for 15minutes at 4 o C. The supernatant was discarded and the pellet was then re-suspended in 500μL of potassium phosphate lysis buffer with Triton-X100. The samples were then sonicated for 8 minutes at 4 o C (a 30 seconds sonication phase followed by a 30 seconds resting phase) using a Bioruptor Plus system (Diagenode, Belgium). 
Results
Alterations in serum and hepatic lipids during mouse pregnancy. To examine the impact of pregnancy on murine lipid metabolism, serum lipids were profiled in mice at different stages of pregnancy: day 7 postcoitum, corresponding to early pregnancy (EP) and days 10, 14 and 18 post-coitum taken to represent advanced pregnancy (AP). Virgin female mice were used as non-pregnant controls. During pregnancy, serum triglyceride concentrations were unchanged in early pregnancy and then gradually increased starting from day 10 of mouse pregnancy onwards (Table 1 ). In contrast, total cholesterol levels decreased in early pregnancy (at day 7), and were further reduced in advanced gestation. The same pattern was observed in the abundance of cholesterol in HDL. Serum levels of free fatty acids were not significantly altered during pregnancy. Since the liver functions as a metabolic hub which regulates all domains of lipid homeostasis (2, 34) , the temporal changes in hepatic lipid profiles in pregnant mice were examined.
In early pregnancy, hepatic triglyceride and cholesterol content was significantly increased whereas the levels of free fatty acids remained unchanged (Table 1) . During advanced pregnancy, concentrations of hepatic triglyceride and cholesterol returned to pre-conception levels.
Alterations in the hepatic LXR transcriptome during pregnancy. Throughout pregnancy the expression of LXR target genes involved in hepatic lipogenesis follow a distinct biphasic pattern. In early pregnancy, consistent with the early-gestational increase in hepatic triglycerides, the transcript levels of the lipogenic targets Fas and Scd1 were substantially raised ( Figure 1A ). In contrast, during advanced pregnancy the mRNA abundance of Srebp1c, Fas and Scd1 was markedly diminished.
LXR controls hepatic cholesterol homeostasis by regulating the scavenger receptor B1 (SRB1), a membrane-bound glycoprotein which mediates the selective and efficient uptake of cholesteryl esters specifically from HDL, as well as the ATP-binding cassette G5 and G8 (ABCG5 and ABCG8) canalicular half-transporters, which form an obligate functional heterodimer that mediates the efflux of hepatic free LXR Modulates Pregnancy Adaptations in Lipid Metabolism 10 cholesterol into bile (3, 21) . Similar to the lipogenic genes, the cholesterol efflux genes Abcg5, Abcg8 and Srb1 were also significantly downregulated during advanced pregnancy in mouse livers when compared to non-pregnant controls ( Figure 1B ). In contrast, the mRNA expression of the ATP-binding cassette A1 (Abca1; an LXR target gene encoding a transmembrane protein, which mediates the transfer of cholesterol and phospholipids to lipid-poor plasma carriers such as apolipoprotein A1 (4)) was significantly raised in early pregnancy and then returned to pre-conception levels during advanced gestation (data not shown).
In the liver, LXRα is the dominant nuclear receptor isoform (1) . Immunoblot analysis revealed that the dynamic alteration in the expression of bona fide targets in the liver during pregnancy were not accompanied by any changes in the protein levels of LXRα (data not shown). The protein abundance of LXRβ also remained unaltered thus excluding a potential compensatory role.
Gene expression analysis revealed that pregnancy has no significant impact on the expression of either
Lxr isoform or its targets in the duodenum (Abca1, Abcg5, Abcg8 and Niemann-pick c1 l1 (Npc1l1)) and primary blood monocytes (Abcg1, Srb1, ADP-ribosylation factor like 7 (Arl7) and LDL receptor (Ldlr))(data not shown) thereby suggesting that changes in LXR activity are unlikely to affect intestinal cholesterol absorption and the reverse transport of sterols from extrahepatic tissues during pregnancy.
LXR remains transcriptionally active during pregnancy. After confirming that changes in the protein availability of LXR could not explain the diminished mRNA levels of hepatic LXR targets during advanced-to-late pregnancy, we tested whether the reduced transcription of these genes could result from loss of LXR function during pregnancy. In order to pharmacologically activate LXR during gestation, pregnant mice were fed standard chow diet or T0901317-supplemented diet for 7, 10, 14 and 18 days
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following the identification of a copulatory plug. Non-pregnant female mice fed a T0901317 or chow diet for the same number of days were used as controls.
Comparison of the pregnant T0901317-fed groups versus pregnancy-matched chow-fed groups revealed that the expression of LXR targets involved in lipogenesis (Srebp1c, Fas and Scd1) and cholesterol efflux (Abcg5 and Abcg8) was markedly increased. These data indicate that LXR is transcriptionally active during pregnancy and pharmacological activation of LXR is able to reverse the reduction in the mRNA levels of key metabolic genes in mouse liver in late pregnancy ( Figure 2A and B). The gene expression changes were functionally confirmed by the significant increase in hepatic triglyceride levels and the reduction in hepatic cholesterol concentrations ( Figure 2C ). Serum lipid profiling revealed that treatment of pregnant mice with T0901317 raises the levels of circulating cholesterol without affecting the levels of circulating triglycerides; these observations are in agreement with previous reports detailing the effect of this synthetic LXR agonist on non-pregnant mice (2, 34).
Activation of LXR contributes to early-pregnancy lipogenesis. To determine whether the adaptations in lipid metabolism observed during normal pregnancy are entirely LXR dependent and therefore completely reversed by the presence of T0901317, pregnant T0901317 mice were compared against nonpregnant diet-matched controls.
T0901317 mimics the gestational signal that promotes lipogenesis during early pregnancy. Gene expression analysis showed that the mRNA levels of the lipogenic LXR targets Fas and Scd1 were not further upregulated in T0901317-fed mice in early pregnancy as compared to diet-matched non-pregnant controls ( Figure 2A ). Also, there were no differences in the hepatic triglyceride content of pregnant and non-pregnant mice challenged with the agonist-supplemented diet for 7 days ( Figure 2C ).
During advanced pregnancy, however, the T0901317 agonist was not able to reverse the gestational changes in triglyceride homeostatic pathways in the liver. Specifically, from day 10 onwards the expression of Srebp1c, Fas and Scd1 was significantly reduced in pregnant mice administered with T0901317 as compared to diet-matched non-pregnant controls (Figure 2A ). Interestingly, serum lipid profiling revealed that the presence of T0901317 abrogated the gestational increase in circulating triglycerides during advanced pregnancy ( Figure 2D ).
Pharmacological activation of LXR had a limited effect on the gestational adaptations in cholesterol metabolism. Lipid profiling showed that the gestational increase in hepatic cholesterol levels on days 7
and 10 of pregnancy were abrogated by the presence of T0901317. In contrast, this synthetic agonist was unable to reverse the gestational changes in the expression of cholesterol homeostatic genes in the liver as evidenced by the fact that the transcript abundance of the cholesterol transporters Abcg5, Abcg8 and Srb1 was lower in pregnant T0901317-fed mice as compared to non-pregnant T0901317-fed controls during advanced pregnancy ( Figure 2B ). Administration of T0901317 to pregnant mice also did not interfere with the pregnancy-associated drop in serum cholesterol as evidenced by the fact that pregnant mice challenged with the agonist-supplemented diet had significantly lower circulating total cholesterol levels from day 10 onwards as compared to diet-matched non-pregnant controls ( Figure 2D ).
Overall these results suggest that pharmacological activation of LXR mimics the early-pregnancy increase in lipogenesis. During advanced pregnancy, however, T0901317 appeared unable to compete with the gestational cues that signal the alterations in triglyceride and cholesterol metabolism and therefore the patterns of gestational adaptations in lipid homeostasis were preserved throughout this period.
LXR is required for lipogenesis during pregnancy.
To delineate the functional importance of LXR in the control of the gestational adaptations in fatty acid and cholesterol metabolism and also to investigate to
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In LXR DKO, the gestational adaptations in hepatic lipogenesis during both early and advanced gestation were lost as evidenced by the fact that no significant changes were detected in the expression of Srebp1c, Fas and Scd1 in the livers of pregnant mice as compared to non-pregnant controls ( Figure 3A) . Lipid quantification studies confirmed that in the absence of Lxrα, β all of the gestational changes in hepatic triglyceride levels were abolished ( Figure 3C ). Serum biochemical profiling also showed that the early-tomid-pregnancy (days 7 and 10) increase in serum triglyceride levels was lost in mice lacking Lxrα, β ( Figure 3D ).
LXR is not required for the gestational adaptations in cholesterol metabolism. Study of WT and LXR
DKO at different stages of pregnancy revealed that the absence of Lxrα, β had no impact on the gestational adaptations in cholesterol homeostasis. Both WT and LXR DKO mice showed significantly reduced expression of the cholesterol efflux transporters Abcg5, Abcg8 and Srb1 on days 14 and 18 of pregnancy ( Figure 3B ). Even though LXR DKO mice had increased levels of hepatic cholesterol, there were no significant pregnancy-induced changes in cholesterol abundance either in the wild-type mice or in the mutants ( Figure 3C ). Serum lipid profiling showed that in both WT and LXR DKO mice, the concentrations of total circulating cholesterol are significantly reduced during pregnancy from day 10 onwards ( Figure 3D ).
Absence of LXR in the mother causes fetoplacental dyslipidemia.
It is recognized that exposure of fetuses to a dyslipidemic environment in utero causes enhanced fetal growth (19, 23, 39) . Given that the absence Figure 4C ). Interestingly, there were no differences in the transcript abundance of Lxrα, the dominant isoform of LXR in the liver, in the heterozygous fetuses as compared to the wild-type controls;
the expression of Lxrβ, however, was significantly downregulated.
Having determined that the fetoplacental hyperlipidemia detected on day 18 of pregnancy in LXR DKO mice is unlikely to result from the augmented biosynthesis of lipids in the fetal liver, we tested whether this phenotype could arise from the deregulated lipid homeostasis in the mother. Biochemical analysis of maternal serum showed that in LXR DKO mice there was marked increase in the levels of free fatty acids on day 18 of pregnancy ( Figure 4D ).
Also, we examined whether the supraphysiological accumulation of free fatty acids in the serum of LXR DKO mice during advanced gestation could result from abnormalities in intestinal lipid absorption. 
Discussion
In the present study, we have identified that changes in LXR signaling influence early-pregnancy lipogenesis in mice. We have shown that pharmacological activation of LXR disrupts lipid biosynthetic pathways in the liver and prevents early-pregnancy hypertriglyceridemia. We have also demonstrated that absence of LXR deregulates maternal lipid homeostasis and enhances white adipose tissue lipolysis which results in the increased accumulation of lipids in the fetal liver.
In this report we demonstrate that LXR targets contribute to early pregnancy lipogenesis as evidenced by LXR is a master regulator not only of fatty acid and triglyceride metabolism, but also of cholesterol homeostasis (27, 30, 32, 40) . Our data demonstrate that gestational adaptations in cholesterol metabolism are independent of LXR. Expression of the cholesterol efflux transporters Abcg5, Abcg8 and Srb1 was downregulated during pregnancy independent of T0901317 challenge or Lxrα, β deletion. Furthermore circulating total cholesterol concentrations were reduced during advanced pregnancy in all of our experimental models. Moreover, our data suggest that gestational changes in the expression of hepatic Our data also revealed that defects in maternal lipid metabolism as a consequence of Lxrα, β deletion cause fetoplacental dyslipidemia in mice. Previous studies have demonstrated that LXR is expressed in white adipose tissue where it is involved in the regulation of cholesterol, free fatty acid and glucose metabolism (6) . In vivo studies have reported that pharmacological activation of LXR increases adipose tissue lipolysis and fatty acid β-oxidation (37) . We show that mice lacking both LXR isoforms have increased white adipose tissue lipolysis later in pregnancy, as evidenced by the raised maternal serum fatty acid levels and the upregulated expression of intracellular lipases in the white fat of these mice.
Moreover, we demonstrated that Lxrα, β deficiency increases the protein levels of ATGL (a key lipolytic enzyme which controls energy homeostasis by catalyzing the rate-limiting step in triglyceride catabolism (14) ) in the adipose tissue of pregnant mice. Our data suggest that changes in HSL phosphorylation are unlikely to contribute to the enhanced lipolytic response in adipose tissue of the Lxrα, β mutant miceOur conclusion that Lxrα, β deficiency promotes white fat lipolysis during advanced gestation is consistent with the observed in vivo phenotype (i.e increased serum free fatty acid concentrations and reduced adipose tissue mass) as wells as the obtained gene and protein expression data. Furthermore, the precise regulation of whole-body lipid homeostasis depends on the continuous crosstalk between liver and adipose tissue. Therefore, we could speculate that the increase in white fat lipolysis in the pregnant LXR DKO mice could occur as a mechanism to compensate for the defects in hepatic lipogenesis in the mother and protect the fetus from any deficiencies in nutrient supply.
A key result from this study was that LXR DKO mice have increased placental weight and enhanced fatty acid and triglyceride accumulation in the placenta later in pregnancy. We also showed that fetuses from
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LXR DKO mice have increased free fatty acids, triglycerides and cholesterol in the liver. Given that there was no induction of lipid biosynthetic pathways in the livers of the Lxrα, β heterozygous fetuses, it is likely that the fetal hepatic hyperlipidemia is a result of the deregulated maternal lipid homeostasis and impaired placental function. Consistent with this, a recent study has linked maternal hyperlipidemia with placental abnormalities and adverse fetal outcomes in cases of gestational diabetes mellitus (GDM) (35) .Moreover, previous studies suggest that maternal adipose tissue lipolytic products are predominantly utilized as ketogenic substrates and the resulting ketone bodies get rapidly transferred to the fetal circulation where they act as lipogenic precursors and energy fuels (15) . Maternally-derived free fatty acids are also able to cross the placenta and accumulate in the fetoplacental compartment (16) . Our results excluded the possibility that the genetic background of the heterozygous fetuses could contribute to their hyperlipidemic phenotype since the mRNA expression of all fatty acid and cholesterol biosynthetic genes, as well as Lxrα, was the same as in the wild-type controls. Previous studies have
shown that gestational pathologies such as GDM and obesity, where maternal plasma levels of circulating lipids are supraphysiologically raised, are associated with fetal overgrowth (large-for-gestational age infants) (13, 28, 33, 36) . Specifically, obese pregnant women typically have significantly increased levels of circulating triglycerides in combination with reduced HDL-cholesterol levels and hyperglycemia as a consequence of exacerbated peripheral insulin resistance in the third trimester of gestation (29). The transplacental delivery of nutrients is quantitatively and qualitatively altered as a result of the increased total lipid content and the accumulation of macrophages and proinflammatory mediators in the placentas of obese women leading to the birth of infants increased neonatal fa t mass and body fat percentage) (8, 24) . Moreover, offspring of women with obesity and/or GDM are not only prone to adverse side effects at birth such as preterm delivery (10) and stillbirth (2) but also have a high risk of developing obesity, impaired glucose tolerance, and type 2 diabetes later in life (4, 7) . All of these reports underscore the importance of thoroughly understanding the molecular determinants of alterations in maternal and fetal lipid metabolism during pregnancy in order to prevent immediate and long-term metabolic diseases. Our
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In conclusion, we present for the first time evidence that LXR is a factor essential for early-pregnancy lipogenesis in mice. We demonstrate that deletion of LXR not only interferes with the pregnancy 
